{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:46:55Z","timestamp":1790984815213,"version":"4.1.0"},"reference-count":27,"publisher":"Termedia Sp. z.o.o.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pol J Radiol"],"abstract":"<jats:p>Prostate cancer is the second most common malignancy in men and a\u00a0leading cause of cancer-related mortality worldwide. Accurate diagnosis is essential to guide therapeutic decision-making and to avoid the overtreatment of indolent tumors. In-bore magnetic resonance imaging-guided prostate biopsy (IB-MRGB) represents the most precise magnetic resonance imaging (MRI)-targeted technique for detecting clinically significant prostate cancer (csPCa). This review summarizes the current evidence, technical aspects, clinical relevance, and future perspectives of IB-MRGB. A\u00a0comprehensive literature review was performed using PubMed, Scopus, and Embase, including studies that evaluated diagnostic performance, procedural workflow, and integration with focal therapies. IB-MRGB demonstrates high sensitivity (80-96%) and specificity (82-90%) for the detection of csPCa. It is particularly effective in biopsy-na\u00efve patients with Prostate Imaging Reporting and Data System (PI-RADS) \u2265 3 lesions, in men with prior negative transrectal ultrasound-guided biopsies but persistent clinical suspicion, and in the context of active surveillance or focal therapy planning. Key advantages include superior lesion targeting and a\u00a0reduction in the overdiagnosis of Gleason 3 + 3 tumors, whereas the main limitations are higher cost, longer procedure duration, and limited MRI availability. IB-MRGB aligns closely with the principles of precision oncology by enabling accurate diagnosis, risk stratification, and optimized treatment planning. Ongoing developments in artificial intelligence, radiomics, and MRI-guided interventions are expected to further enhance diagnostic efficiency and expand the clinical role of this technique.<\/jats:p>","DOI":"10.5114\/pjr\/212568","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T13:57:33Z","timestamp":1772114253000},"page":"68-74","source":"Crossref","is-referenced-by-count":1,"title":["In-bore MRI-guided prostate biopsy: current evidence, clinical applications, and future directions"],"prefix":"10.5114","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3710-9037","authenticated-orcid":false,"given":"Katarzyna","family":"Skrobisz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2234-1151","authenticated-orcid":false,"given":"Wojciech","family":"Polom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5297-331X","authenticated-orcid":false,"given":"Justyna","family":"Rembak-Szynkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Matuszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"ref-1676157","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209 249.","DOI":"10.3322\/caac.21660"},{"key":"ref-1676158","doi-asserted-by":"crossref","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer \u2013 2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol 2024; 86: 148-163.","DOI":"10.1016\/j.eururo.2024.03.027"},{"key":"ref-1676159","doi-asserted-by":"crossref","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al.; PRECISION Study Group Collaborators. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 2018; 378: 1767-1777.","DOI":"10.1056\/NEJMoa1801993"},{"key":"ref-1676160","doi-asserted-by":"crossref","unstructured":"Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011; 186: 1830 1834.","DOI":"10.1016\/j.juro.2011.06.057"},{"key":"ref-1676161","doi-asserted-by":"crossref","unstructured":"Turkbey B, Choyke PL. Multiparametric MRI and prostate cancer diagnosis and risk stratification. Curr Opin Urol 2012; 22: 310 315.","DOI":"10.1097\/MOU.0b013e32835481c2"},{"key":"ref-1676162","doi-asserted-by":"crossref","unstructured":"de Rooij M, Hamoen EHJ, F\u00fctterer JJ, Barentsz JO, Rovers MM. Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. Eur Urol 2014; 65: 230 238.","DOI":"10.2214\/AJR.13.11046"},{"key":"ref-1676163","doi-asserted-by":"crossref","unstructured":"Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Diagnostic performance of PI-RADS v2 for detection of prostate cancer: systematic review and meta-analysis. Eur Urol 2017; 72: 177 188.","DOI":"10.1016\/j.eururo.2017.01.042"},{"key":"ref-1676164","doi-asserted-by":"crossref","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. PI-RADS prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol 2019; 76: 340 351.","DOI":"10.1016\/j.eururo.2019.02.033"},{"key":"ref-1676165","doi-asserted-by":"crossref","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 2018; 378: 1767 1777.","DOI":"10.1056\/NEJMoa1801993"},{"key":"ref-1676166","doi-asserted-by":"crossref","unstructured":"Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, et al. Comparison of MR\/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 2015; 313: 390 397.","DOI":"10.1001\/jama.2014.17942"},{"key":"ref-1676167","doi-asserted-by":"crossref","unstructured":"Wegelin O, van Melick HHE, Hooft L, Bosch JLHR, Reitsma HB, Barentsz JO, Somford DM. Comparing three different techniques for magnetic resonance imaging-targeted prostate biopsies: a systematic review of in-bore versus MRI-TRUS fusion versus cognitive registration. Is there a preferred technique? Eur Urol 2017; 71: 517-531.","DOI":"10.1016\/j.eururo.2016.07.041"},{"key":"ref-1676168","doi-asserted-by":"crossref","unstructured":"Schoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink MG. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol 2015; 68: 438-450.","DOI":"10.1016\/j.eururo.2014.11.037"},{"key":"ref-1676169","unstructured":"Franiel T, Hamm B, Hricak H. MRI-guided prostate interventions: in-bore biopsy and focal therapy. Radiology 2014; 271: 901 915."},{"key":"ref-1676170","doi-asserted-by":"crossref","unstructured":"Penzkofer T, Tuncali K, Fedorov A, Song SE, Tokuda J, Fennessy FM, et al. Transperineal in-bore 3-T MR imaging-guided prostate biopsy: a prospective clinical observational study. Radiology 2015; 274: 170-180.","DOI":"10.1148\/radiol.14140221"},{"key":"ref-1676171","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.8427"},{"key":"ref-1676172","doi-asserted-by":"crossref","unstructured":"Bass EJ, Pantovic A, Connor MJ, Loeb S, Rastinehad AR, Winkler M, et al. Diagnostic accuracy of magnetic resonance imaging-targeted biopsy techniques compared to transrectal ultrasound-guided biopsy of the prostate: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2022; 25: 174-179.","DOI":"10.1038\/s41391-021-00449-7"},{"key":"ref-1676173","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15245825"},{"key":"ref-1676174","doi-asserted-by":"crossref","unstructured":"Stavrinides V, Giganti F, Emberton M, Moore CM. MRI in active surveillance: a critical review. Prostate Cancer Prostatic Dis 2019; 22: 5-15.","DOI":"10.1038\/s41391-018-0077-2"},{"key":"ref-1676175","doi-asserted-by":"crossref","unstructured":"Cornud F, Bomers J, F\u00fctterer JJ, Ghai S, Reijnen JS, Tempany C. MR imaging-guided prostate interventional imaging: ready for a clinical use? Diagn Interv Imaging 2018; 99: 743-753.","DOI":"10.1016\/j.diii.2018.08.002"},{"key":"ref-1676176","doi-asserted-by":"crossref","unstructured":"Elkhoury FF, Simopoulos DN, Marks LS. MR-guided biopsy and focal therapy: new options for prostate cancer management. Curr Opin Urol 2018; 28: 93-101.","DOI":"10.1097\/MOU.0000000000000471"},{"key":"ref-1676177","doi-asserted-by":"crossref","unstructured":"Rembak Szynkiewicz J, Wojcieszek P, Hebda A, Mazgaj P, Badzi\u0144ski A, Stasik-Pres G, et al. In bore MR prostate biopsy \u2013 initial experience. Endokrynol Pol 2022; 73: 712 724.","DOI":"10.5603\/EP.a2022.0042"},{"key":"ref-1676178","doi-asserted-by":"crossref","unstructured":"Mertan FV, Greer MD, Borofsky S, Kabakus IM, Merino MJ, Wood BJ, et al. Multiparametric magnetic resonance imaging of recurrent prostate cancer. Top Magn Reson Imaging 2016; 25: 139 147.","DOI":"10.1097\/RMR.0000000000000088"},{"key":"ref-1676179","doi-asserted-by":"crossref","unstructured":"Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, et al. 68Ga-PSMA-11 PET\/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng\/mL: impact on salvage radiotherapy planning. J Nucl Med 2018; 59: 230-237.","DOI":"10.2967\/jnumed.117.201749"},{"key":"ref-1676180","doi-asserted-by":"crossref","unstructured":"Cuocolo R, Cipullo MB, Stanzione A, Romeo V, Green R, Cantoni V, et al. Machine learning for the identification of clinically significant prostate cancer on MRI: a meta-analysis. Eur Radiol 2020; 30: 6877-6887.","DOI":"10.1007\/s00330-020-07027-w"},{"key":"ref-1676181","doi-asserted-by":"crossref","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate Imaging Reporting and Data System version 2.1: 2019 update of Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 2019; 76: 340 351.","DOI":"10.1016\/j.eururo.2019.02.033"},{"key":"ref-1676182","doi-asserted-by":"publisher","DOI":"10.3390\/siuj6010010"},{"key":"ref-1676183","doi-asserted-by":"crossref","unstructured":"Oprea-Lager DE, MacLennan S, Bjartell A, Briganti A, Burger IA, de Jong I, et al. European Association of Nuclear Medicine Focus 5: consensus on molecular imaging and theranostics in prostate cancer. Eur Urol 2024; 85: 49-60.","DOI":"10.1016\/j.eururo.2023.09.003"}],"container-title":["Polish Journal of Radiology"],"original-title":[],"link":[{"URL":"https:\/\/www.polradiol.com\/pdf-212568-135921","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.polradiol.com\/pdf-212568-135921","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T13:57:36Z","timestamp":1772114256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.polradiol.com\/In-bore-MRI-guided-prostate-biopsy-current-evidence-clinical-applications-and-future,212568,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"alternative-id":["212568"],"URL":"https:\/\/doi.org\/10.5114\/pjr\/212568","relation":{},"ISSN":["1899-0967"],"issn-type":[{"value":"1899-0967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,13]]}}}